Continuous Intraosseous Vascular Access Over 48 Hours

Vidacare

Status: Completed

Conditions: Intraosseous Vascular Access

Treatments: Device: EZ-IO

Study type: Interventional

Funder types: Industry

Identifiers

NCT01866475

2011-16

Details and patient eligibility

About

A prospective study to determine the safety of intraosseous (IO) access for a period up to 48 hours in healthy adult volunteers and volunteers with a history of mild to moderate renal disease and/or controlled diabetes.

Full description

A prospective, study to determine the safety of intraosseous (IO) access for a period up to 48 hours, in healthy adult volunteers and volunteers with a history of being health-compromised, including patients with mild to moderate renal disease (National Health and Nutrition Examination Survey Stage 1 to 3) and/or patients with controlled diabetes. Subjects will be randomized to receive IO access in the proximal tibia insertion site or the proximal humerus insertion site using the EZ-IO intraosseous vascular access system. The hypothesis is that there will be no serious complications for the subjects during a 48 hour IO catheter dwell time in either place.

Enrollment: 127 patients

Sex: All

Ages: 21+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 21 years or older
• Self Identifying as having poor vascular access
• Healthy or Having at least one of the following conditions:
• Controlled diabetes, as evidenced by a glycosylated hemoglobin A1c (HbA1c) value of less than or equal to 8% at the time of screening. or
• Renal disease, Stages 1 to 3, as evidenced by the presence of albuminuria at the time of screening. Subjects albumin-creatinine ratio (ACR) must fall within the microalbuminuria or macroalbuminuria values: Microalbuminuria - ACR 17-250 mcg/mg for men; 25-355 mcg/mg for women or, Macroalbuminuria- ACR >250 mcg/mg for men; >355 mcg/mg for women

Exclusion criteria

• Imprisoned
• Self identifying as pregnant
• Cognitively impaired
• Fracture in target bone
• Excessive tissue and/or absence of adequated anatomical landmarks in target bone
• Signs and symptoms of infection in target area
• IO insertion in past 48 hours, prosthetic limb or joint or other significant orthopedic procedure in target bone
• Intravenous infusion within the past 30 days
• Current use of anti-coagulants
• Previous adverse reaction or known allergy to Lidocaine
• Current cardiac condition requiring pacemaker
• Currently taking beta blockers or calcium channel blockers for heart arrhythmia (use of beta blockers or calcium channel blocker for hypertension is allowed when indication of hypertension can be confirmed by physician
• Previous surgery for peripheral arterial disease
• History of ulcers to the extremities
• History of bilateral lymph node dissection in the arms or legs
• Known sickle-cell disease
• signs or symptoms of vascular disease or vascular insufficiencies to the extremities, as identified upon physical examination
• History of peripheral vascular disease
• Hyperkalemia as evidenced by potassium level greater than 5.1 mmol/L the upper limit of hte normal reference range at screening

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

127 participants in 4 patient groups

Renal Disease

Active Comparator group

Description:

Those with mild to moderate renal disease and had an EZ-IO for 48 hours

Treatment:

Device: EZ-IO

Diabetes

Active Comparator group

Description:

Those with controlled diabetes and had an EZ-IO for 48 hours

Treatment:

Device: EZ-IO

Renal disease and diabetes

Active Comparator group

Description:

Those with both mild to moderate renal disease and controlled diabetes and had an EZ-IO for 48 hours

Treatment:

Device: EZ-IO

Healthy adults

Active Comparator group

Description:

Those who are healthy, defined as lacking co-morbidities that are a study exclusion, and had an EZ-IO for 48 hours

Treatment:

Device: EZ-IO